{
    "nctId": "NCT00317603",
    "briefTitle": "Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients",
    "officialTitle": "A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Metastatic Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Minimum Number of Vaccine Doses Created Using Participant Tumor Sample",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed Stage IV breast cancer\n* Prior banked malignant effusion or significant malignant effusion for tumor harvest or surgically-accessible tumor nodule of at least 2cm in greatest diameter by physical exam, magnetic resonance imaging (MRI) or computed tomography (CT) scan\n* Must have received at least one prior regimen of chemotherapy for metastatic disease\n* Patients with HER2 positive tumors must have received at least one prior trastuzumab-based therapy in the metastatic setting, and may not receive trastuzumab therapy and vaccine treatment concurrently\n* Patients may receive concurrent bisphosphonate therapy and/or erythropoetin therapy at any point while on study\n* ECOG performance status 0 or 1\n* Estimated life expectancy of greater than or equal to 6 months\n* 18 years of age or older\n* Greater than 4 weeks from immunotherapy, or systemic glucocorticoid therapy\n* Adequate recovery from drug-related toxicities from prior systemic therapies\n* Adequate recovery from recent surgery and radiation therapy\n* Greater than 6 months since bone marrow or peripheral blood stem cell transplant\n\nExclusion Criteria:\n\n* Urgent need for cytotoxic chemotherapy, radiotherapy, or surgery in the next 60 days\n* Uncontrolled active infection or illness\n* Psychiatric illness/social situation that would limit study compliance\n* Pregnant or nursing mothers\n* Evidence of HIV infection\n* Previous participation in an adenovirus-based trial\n* Concurrent invasive malignancy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}